title: Generic Pharmaceutical Association (GPhA) - 2015 Annual Meeting (February 9-11, 2015 - Miami Beach, Florida, USA).
abstract: The Generic Pharmaceutical Association (GPhA) chairman Craig Wheeler (Momenta Pharmaceuticals), welcomed attendees to the 2015 Annual Meeting by reflecting on the contributions of the generic industry over the past year and some of the challenges that lie ahead. In 2014, 86% of prescriptions dispensed in the U.S. were generic, contributing to the USD 1.4 trillion savings generated by the industry since its inception; however, there are still many challenges to face, including consolidation of customers, lag in Abbreviated New Drug Application (ANDA) approval timelines, restrictive Risk Evaluation and Mitigation Strategy (REMS) programs and labeling legislations. The continued drive into the branded business by many GPhA member companies has resulted in the association planning a structural division for companies involved in biologic and biosimilar products. During the 3-day meeting, attendees listened to expert panels discuss major business, regulatory and market trends developing in the generic industry, with insights from the U.S. Food and Drug Administration (FDA) and market analysts. The meeting also provided attendees with numerous opportunities to socialize and network with key decision makers in the industry.
authors.affiliation: Thomson Reuters, Portland, Maryland, USA. molly.bowman@thomsonreuters.com.
authors.forename: M
authors.initials: M
authors.lastname: Bowman
mesh_terms: D004345:Drug Industry; D016568:Drugs, Generic; D006801:Humans
chemical_list: D016568:Drugs, Generic
keywords: ANDA; FDA; GDUFA; Generics